PA
RYTM icon

Perceptive Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Perceptive Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206M Sell
2,373,795
-172,596
-7% -$16.8M 4.03% 6
2025
Q4 		$273M Buy
2,546,391
+107,422
+4% +$11.4M 4.86% 3
2025
Q3 		$288M Buy
2,438,969
+20,670
+0.9% +$1.92M 8.33% 1
2025
Q2 		$153M Sell
2,418,299
-130,146
-5% -$7.97M 5.67% 4
2025
Q1 		$135M Sell
2,548,445
-1,132,028
-31% -$62.8M 4.77% 5
2024
Q4 		$206M Buy
3,680,473
+120,259
+3% +$6.64M 5.68% 4
2024
Q3 		$187M Buy
3,560,214
+113,635
+3% +$5.44M 3.95% 6
2024
Q2 		$142M Buy
3,446,579
+178,000
+5% +$7.11M 3.41% 6
2024
Q1 		$142M Buy
3,268,579
+1,114,469
+52% +$48.8M 2.48% 8
2023
Q4 		$99M Buy
2,154,110
+1,773,282
+466% +$55.9M 2.21% 8
2023
Q3 		$8.73M Buy
+380,828
New +$8.53M 0.29% 62
2020
Q2 		– Sell
-170,859
Closed -$2.6M – 135
2020
Q1 		$2.6M Hold
170,859
– – 0.07% 89
2019
Q4 		$3.92M Buy
+170,859
New +$3.8M 0.08% 84
2019
Q3 		– Sell
-262,970
Closed -$5.79M – 119
2019
Q2 		$5.79M Sell
262,970
-240,000
-48% -$6.06M 0.13% 78
2019
Q1 		$13.8M Sell
502,970
-6,216
-1% -$179K 0.39% 51
2018
Q4 		$13.8M Sell
509,186
-155,000
-23% -$4.28M 0.52% 43
2018
Q3 		$19.4M Sell
664,186
-136,500
-17% -$4.31M 0.52% 43
2018
Q2 		$25M Buy
800,686
+208,400
+35% +$5.7M 0.66% 41
2018
Q1 		$11.8M Sell
592,286
-152,849
-21% -$4.06M 0.33% 57
2017
Q4 		$21.7M Buy
+745,135
New +$19.7M 0.72% 36

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's RYTM Position: Q1 2026 in Review

Perceptive Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 6.8% in Q1 2026, selling an estimated $16.8M and leaving 2,373,795 shares worth $206M. The position accounts for 4.03% of the portfolio, ranked #6.

Perceptive Advisors first reported a position in RYTM in Q4 2017 and has held it in 20 quarters since. The position peaked at $288M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Perceptive Advisors held 2,373,795 shares of Rhythm Pharmaceuticals worth $206M as of Q1 2026.
  • Perceptive Advisors sold 172,596 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $16.8M.
  • Rhythm Pharmaceuticals made up 4.03% of Perceptive Advisors's portfolio in Q1 2026, its #6 holding.
  • Perceptive Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
  • Perceptive Advisors's Rhythm Pharmaceuticals position peaked at $288M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.